<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="27" ids="27300">Vitamin D</z:chebi> insufficiency is commonly observed in the general population; observational studies have suggested an association with increased risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> development </plain></SENT>
<SENT sid="1" pm="."><plain>We examined the clinical and prognostic relevance of low plasma levels of 25-hydroxyvitamin D (25[OH]D) in myeloproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (MPN) and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>A total of 409 patients were studied: 247 (60%) with primary <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> (PMF), 74 (18%) with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, 63 (15%) with <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>), and 25 (6%) with <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e> (ET) </plain></SENT>
<SENT sid="3" pm="."><plain>Plasma 25(OH)D levels were measured by liquid chromatography-tandem mass spectrometry; a level lower than 25 ng/mL indicated <z:chebi fb="27" ids="27300">vitamin D</z:chebi> insufficiency and a level lower than 10 ng/mL indicated severe deficiency </plain></SENT>
<SENT sid="4" pm="."><plain>The proportion of patients with 25(OH)D insufficiency was significantly greater in PMF (48%) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> (43%) when compared with ET (28%) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (28%) (P = 0.01) </plain></SENT>
<SENT sid="5" pm="."><plain>Severe 25(OH)D deficiency was significantly more frequent in ET (12%) and PMF (9%), compared with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> (3%) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (1%) (P = 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>There were no significant correlations between 25(OH)D insufficiency, or severe deficiency, and a variety of clinical or laboratory variables in PMF, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, <z:chebi fb="27" ids="27300">Vitamin D</z:chebi> insufficiency did not influence either overall or <z:hpo ids='HP_0001909'>leukemia</z:hpo>-free survival in PMF, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> (P &gt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>We conclude that while <z:e sem="disease" ids="C1510471" disease_type="Disease or Syndrome" abbrv="">hypovitaminosis</z:e> D is relatively common in MPN and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, its clinical relevance for prognosis is limited </plain></SENT>
</text></document>